Indian Angelman Syndrome Treatment market size stood at around USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.
Angelman Syndrome is a rare genetic disorder that primarily affects the nervous system. Angelman syndrome is caused by a loss of function in the UBE3A gene on the maternal 15th chromosome. People suffering from Angelman syndrome frequently laugh and smile, and have excitable personalities. The symptoms of Angelman syndrome include seizures, lack of speech, and balance issues. Other symptoms are tongue thrusting, developmental delays, jerky movements, small head size with flatness in the back of the head, and others. Presently, therapies for Angelman syndrome are supportive and symptomatic. The diagnosis of Angelman syndrome is done through a genetic test, in which a small amount of blood is taken from the patient and sent to a lab for testing. Tests review DNA pattern, gene mutation, and missing chromosomes. Epilepsy is generally related with Angelman syndrome, which causes jerky movements, seizures, and prolonged periods of unresponsiveness, known as nonconvulsive status epilepticus (NCSE). Some of the commonly used medications for seizures include sodium valproate, phenobarbital, topiramate, clonazepam, levetiracetam, and others.
The Angelman syndrome treatment market is expected to grow over the forecast period, due to increasing research activities and R&D expenditure. Government initiatives in developing new treatment options for Angelman syndrome are expected to drive the growth of the Indian Angelman syndrome treatment market over the forecast period 2019-2028. Furthermore, the effectiveness of the treatment by reducing the effect of the symptoms is also driving the growth of the Indian Angelman syndrome treatment market. Improvements in the healthcare sector are further facilitating the growth of the Angelman syndrome treatment market.